Mark Lebovitch Discusses Impact on Securities Litigation in D&O Market at Advisen Webinar

February 1, 2012

BLB&G partner Mark Lebovitch was as a featured panelist in the Year-End Securities Litigation Webinar, hosted by Advisen on February 1, 2012.

Mr. Lebovitch, alongside an esteemed panel of experts, reviewed securities litigation activity in 2011 and its impact on the D&O Market, among other topics.

Mr. Lebovitch has prosecuted numerous high-profile cases on behalf of institutional investors to preliminary injunctions and through trial. He has obtained hundreds of millions of dollars for investors and achieved unprecedented corporate governance improvements in matters including the Pfizer Derivative Litigation, the Landry’s going-private litigation, and In re ACS Shareholders Litigation, among others.  Most recently, he served as a co-lead trial counsel in the landmark trial challenging the Airgas Products, Inc. Board’s use of a poison pill.